Filip Janku Sells 6,000 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 6,000 shares of Monte Rosa Therapeutics stock in a transaction on Monday, June 29th. The shares were sold at an average price of $22.95, for a total value of $137,700.00. Following the transaction, the insider owned 59,992 shares in the company, valued at $1,376,816.40. This trade represents a 9.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Filip Janku also recently made the following trade(s):

• On Tuesday, June 30th, Filip Janku sold 5,407 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $24.50, for a total value of $132,471.50.
• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.22, for a total value of $239,505.90.
• On Wednesday, June 24th, Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $21.42, for a total value of $642,600.00.

Monte Rosa Therapeutics Trading Down 0.7%

Shares of NASDAQ:GLUE opened at $24.02 on Thursday. The stock has a 50 day moving average of $19.24 and a 200 day moving average of $18.79. The company has a market cap of $2.03 billion, a PE ratio of -16.23 and a beta of 1.55. Monte Rosa Therapeutics, Inc. has a 12-month low of $4.12 and a 12-month high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The firm had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. Equities research analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Monte Rosa Therapeutics

A number of hedge funds have recently bought and sold shares of GLUE. State Street Corp increased its holdings in shares of Monte Rosa Therapeutics by 148.9% in the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after buying an additional 1,260,707 shares during the last quarter. MPM Bioimpact LLC bought a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at about $18,399,000. AQR Capital Management LLC grew its position in Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after acquiring an additional 1,054,406 shares in the last quarter. Braidwell LP purchased a new position in Monte Rosa Therapeutics in the fourth quarter worth about $14,870,000. Finally, Vestal Point Capital LP bought a new stake in Monte Rosa Therapeutics during the third quarter worth approximately $5,928,000. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on GLUE shares. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. JPMorgan Chase & Co. increased their price target on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Wells Fargo & Company lowered their price objective on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Guggenheim upped their price objective on Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.33.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.